人工智能诊断公司Cancilico完成250万欧元种子轮融资，加速推进AI驱动的骨髓诊断技术-动脉网

Cancilico Raises €2.5M to Scale AI-Powered Bone Marrow Diagnostics

D-Pharm 等信源发布 2026-01-26 11:17



可切换为仅中文







Cancilico, an AI diagnostics startup specializing in

Cancilico，一家专注于人工智能诊断的初创公司，

blood cancer

血液癌症

, announced the successful closing of its €2.5 million Seed financing round. The investment was led by a strong consortium including High-Tech Gründerfonds (HTGF), TGFS – Technologiegründerfonds Sachsen, GEDAD GmbH (investment vehicle of Ehninger family), and ROI Verwaltungsgesellschaft (Roland Oetker)..

，宣布成功完成了250万欧元的种子轮融资。本轮融资由一个强大的财团领投，包括High-Tech Gründerfonds（HTGF）、TGFS – Technologiegründerfonds Sachsen、GEDAD GmbH（Ehninger家族的投资工具）和ROI Verwaltungsgesellschaft（Roland Oetker）。

The funding will accelerate Cancilico’s mission to establish its AI-based diagnostic software MyeloAID as a routine tool to improve the standard of care for blood cancer patients worldwide and to accelerate digital biomarker development in hematological malignancies.

这笔资金将加速Cancilico的使命，使其基于人工智能的诊断软件MyeloAID成为提高全球血液癌症患者护理标准的常规工具，并加速在血液恶性肿瘤领域的数字生物标志物开发。

MyeloAID aims to become the game-changer in the diagnosis of hematological malignancies by using advanced artificial intelligence to analyze bone marrow samples with unprecedented speed and accuracy. The underlying data model of Cancilico’s AI-diagnosis is based on a large validated data set of various malignancies as well as data from healthy individuals.

MyeloAID 力求通过使用先进的人工智能技术，以前所未有的速度和准确性分析骨髓样本，从而成为血液恶性肿瘤诊断的变革者。Cancilico 的人工智能诊断背后的数据模型基于一个包含多种恶性肿瘤及健康个体数据的大规模验证数据集。

Partnerships with hematopathology centers further enhance the data model and cooperation with pharma partners show initial results for accelerated development of biomarkers and therapeutic options for hematological malignancies..

与血液病理学中心的合作进一步增强了数据模型，与制药合作伙伴的合作显示了加速开发血液系统恶性肿瘤生物标志物和治疗方案的初步成果。

Aignostics secures $34 million Series B to improve precision medicine with AI

Aignostics 获得 3400 万美元 B 轮融资，利用人工智能提升精准医疗。

Investments will support new product offerings, US expansion, and development of pathology foundation models

投资将支持新产品推出、美国市场扩张以及病理学基础模型的开发。

Read news

读新闻

Especially in times when we face a shortage of trained hematologists, such supporting technologies are urgently needed to ensure clinical availability and precision medicine. A unique feature of MyeloAID is the design as a platform-independent solution. The technology can be implemented on any standard imaging microscope or scanner, allowing laboratories to upgrade their current diagnostic capabilities without replacing existing hardware infrastructure.

尤其是在我们面临训练有素的血液病学家短缺的时代，这样的支持性技术尤为迫切需要，以确保临床可用性和精准医疗。MyeloAID 的一个独特之处在于其设计为独立于平台的解决方案。该技术可以应用于任何标准成像显微镜或扫描仪上，使实验室能够在不更换现有硬件基础设施的情况下提升其当前的诊断能力。

Further, the AI-diagnosis is already available and used as a RUO variant via Smart In Media’s PathoZoom® Scan & LiveView Suite..

此外，人工智能诊断已经可以通过Smart In Media的PathoZoom® Scan & LiveView Suite以研究用途（RUO）的形式提供和使用。

“We are convinced to invest in a winning team and a superior technology that has already gained commercial traction with its ‘Research Use Only’ data models,” said Dr. Jörg Traub, Principal at HTGF. “The team combines entrepreneurial spirit with deep technical and clinical knowledge. Cancilico has established a convincing AI model using training data that includes not only diseased patient samples but also healthy datasets, allowing for better and faster classification.”.

“我们坚信投资于一支获胜的团队和一项卓越的技术，其‘仅供研究使用’的数据模型已经获得了商业上的认可，” HTGF的负责人Jörg Traub博士表示。“这支团队将企业家精神与深厚的技术和临床知识相结合。Cancilico建立了一个令人信服的人工智能模型，其训练数据不仅包括患病患者的样本，还包括健康数据集，从而实现更好、更快的分类。”

The experienced and multidisciplinary team including CEO Markus Badstübner, CMO Dr. Moritz Middeke, Tim Schmittmann, Sebastian Riechert, Dr. Jan Eckardt, Dr. Karsten Wendt, and Angel Investor Prof. Gerhard Ehninger, operates at the intersection of data science and clinical hematology.

由首席执行官马库斯·巴德施图伯纳、首席营销官莫里茨·米德克博士、蒂姆·施密特曼、塞巴斯蒂安·里希特、扬·艾克哈特博士、卡斯滕·温特博士以及天使投资人格哈德·埃内尔教授组成的经验丰富且多学科的团队，致力于数据科学与临床血液学的交叉领域。

“We are facing a global shortage of hematologists, yet the complexity of diagnostic cases is rising,” said Markus Badstübner, CEO and Co-Founder of Cancilico. “Our goal is to democratize access to expert-level diagnostics. This investment allows us to navigate the FDA and CE-IVDR regulatory landscapes and bring a tool to market that integrates seamlessly with existing lab hardware to improve patient outcomes without heavy capital expenditure.”.

“我们面临着全球血液病学家短缺的问题，而诊断病例的复杂性却在不断增加，”Cancilico首席执行官兼联合创始人马库斯·巴德施图伯表示。“我们的目标是使专家级诊断普及化。这项投资使我们能够应对FDA和CE-IVDR的监管环境，并推出一款与现有实验室硬件无缝集成的工具，从而在不增加大量资本支出的情况下改善患者治疗效果。”

“Bone marrow analysis is one of the most complex and time-intensive disciplines in hematology,” added Dr. Moritz Middeke, CMO and Co-Founder. “By training our AI on a diverse range of healthy and pathological datasets, we developed a tool that acts as a highly skilled ‘digital colleague’. This funding is a crucial step toward bringing this technology to the labs, where it will help to make faster, more accurate diagnoses for blood cancer patients.”.

“骨髓分析是血液学中最复杂且最耗时的学科之一，”首席医学官兼联合创始人莫里茨·米德克博士补充道。“通过使用健康和病理数据集的多样性来训练我们的AI，我们开发了一种如同高度熟练的‘数字同事’一样的工具。这笔资金是将这项技术引入实验室的关键一步，它将有助于为血癌患者提供更快、更准确的诊断。”

https://www.bionity.com/en/news/1187946/cancilicoraises-2-5mtoscaleai-poweredbonemarrowdiagnostics.html

How stem cells and immune cells communicate

干细胞和免疫细胞如何通讯

Lisec Artz Award for Simon Haas: Groundbreaking discovery of an unknown protective mechanism against blood cancer from stem cells

利塞茨艺术奖授予西蒙·哈斯：发现未知的干细胞抗癌保护机制

Read news

读新闻